Skip to content

Scientific publications

  • article Vachon K, Tardif MA, Paillé É and Leblanc MH, Cantin G, Lemieux C, Gallagher G

    Determining the best premedication regimen to prevent rabbit anti-human thymocyte globulin infusion-associated reactions: A retrospective study comparing two hematopoietic stem …

    Transpl Immunol 89 2025.

    DOI PUBMED
  • article Pelland AA, Deschênes-Simard X, Savard X, Giguère P, Spillane D, Barabé F, Laroche V, Munger M, Gallagher G, Marcoux N, Cantin G, Chénard-Poirier M, Delage R, Lalancette M, Veilleux O, Assouline SE, Lemieux C

    Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study

    Leuk Lymphoma 65 (13), 2024.

    DOI PUBMED
  • article Leblanc D, Cantin G, Desnoyers A, Dufresne J, Masucci GL, Panet-Raymond V, Poirier É and Soldera S, Gingras I

    Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion

    Curr Oncol 30 (2), 2023.

    DOI PUBMED
  • article Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot JL, Tausch E, Trunzer K, Robson S, Gresko E, Böttcher S, Foà R, Stilgenbauer S, Leblond V

    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

    Leukemia 34 (2), 2020.

    DOI PUBMED
  • article Lemieux J, Forget G, Brochu O, Provencher L, Cantin G, Desbiens C, Doyle C, Poirier B, Camden S, Durocher M

    Evaluation of eligibility and recruitment in breast cancer clinical trials

    Breast 23 (4), 2014.

    DOI PUBMED
  • article Poirier E, Desbiens C, Poirier B, Hogue JC, Lemieux J, Doyle C, Leblond AF, Cote I, Cantin G, Provencher L

    Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients

    Ann Pharmacother 48 (4), 2014.

    DOI PUBMED
  • article Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM

    A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute o…

    Blood 121 (9), 2013.

    DOI PUBMED
  • article Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N and

    CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the Mab…

    Lancet Oncol 12 (11), 2011.

    DOI PUBMED
  • article Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M

    Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical…

    J Clin Oncol 29 (25), 2011.

    DOI PUBMED